Marketdash
Back to News

Alpha Tau Medical Jumps 25% After Treating First Brain Cancer Patient With Novel Radiation Therapy

MarketDash Editorial Team
2 hours ago
Alpha Tau Medical's stock surged over 25% in after-hours trading following the treatment of its first patient with Alpha DaRT therapy in a pilot study targeting one of medicine's most challenging cancers: recurrent glioblastoma.

Alpha Tau Medical Ltd. (DRTS) shares climbed 25.26% in after-hours trading to $5.30 on Tuesday, and there's a pretty good reason why: the Jerusalem-based company just treated its first patient with a novel radiation therapy that could change the game for one of the hardest cancers to treat.

Breaking New Ground in Brain Cancer Treatment

The milestone treatment took place at The Ohio State University Center in Columbus, Ohio, where a multidisciplinary team deployed Alpha Tau's Alpha DaRT alpha-radiation cancer therapy on a patient with recurrent glioblastoma multiforme. If you're not familiar with glioblastoma, just know it's about as bad as cancer diagnoses get.

The procedure was led by Principal Investigator and Radiation Oncologist Joshua D. Palmer, Medical Physicist Michael Degnan, and Neurosurgeon J. Bradley Elder. Dr. Elder reported that the novel delivery device enabled placement of Alpha DaRT sources in a precise radial configuration, achieving over 95% coverage of the tumor volume.

Dr. Palmer put it plainly: "Patients with recurrent glioblastoma face one of the most difficult cancer diagnoses in medicine. There is an urgent unmet need for new therapeutic approaches that can be delivered locally while minimizing harm to surrounding healthy brain tissue."

FDA Fast-Track Status Signals Confidence

Uzi Sofer, CEO of Alpha Tau Medical, noted that the pilot study supports the company's strategy to treat cancer patients with high unmet needs. And the FDA seems to agree this is worth accelerating.

To speed up the marketing of Alpha DaRT treatment, the company was granted Food and Drug Administration Breakthrough Device Designation. They've also been accepted into the FDA's Total Product Life Cycle Advisory Program, a voluntary pilot program intended to promote innovative medical device development through early FDA engagement. Translation: the FDA is giving Alpha Tau a shorter path to market because they think this technology could actually help people who have few other options.

What the Market Is Saying

The after-hours pop reflects investor optimism about Alpha Tau's prospects. DRTS shares have gained 39.60% over the past year, and the oncology therapeutics company now carries a market capitalization of $363.47 million.

The stock closed regular trading on Tuesday at $4.23, up 8.74%, before rocketing higher after hours. Shares have traded in an annual range of $2.30 to $4.69, meaning the after-hours price of $5.30 represents a new high for the year.

With momentum in the 79th percentile, DRTS is experiencing short-term consolidation along with medium and long-term upward movement. For a small-cap biotech tackling one of medicine's toughest challenges, that kind of momentum tells you the market is paying attention.

Back to News

Alpha Tau Medical Jumps 25% After Treating First Brain Cancer Patient With Novel Radiation Therapy

MarketDash Editorial Team
2 hours ago
Alpha Tau Medical's stock surged over 25% in after-hours trading following the treatment of its first patient with Alpha DaRT therapy in a pilot study targeting one of medicine's most challenging cancers: recurrent glioblastoma.

Alpha Tau Medical Ltd. (DRTS) shares climbed 25.26% in after-hours trading to $5.30 on Tuesday, and there's a pretty good reason why: the Jerusalem-based company just treated its first patient with a novel radiation therapy that could change the game for one of the hardest cancers to treat.

Breaking New Ground in Brain Cancer Treatment

The milestone treatment took place at The Ohio State University Center in Columbus, Ohio, where a multidisciplinary team deployed Alpha Tau's Alpha DaRT alpha-radiation cancer therapy on a patient with recurrent glioblastoma multiforme. If you're not familiar with glioblastoma, just know it's about as bad as cancer diagnoses get.

The procedure was led by Principal Investigator and Radiation Oncologist Joshua D. Palmer, Medical Physicist Michael Degnan, and Neurosurgeon J. Bradley Elder. Dr. Elder reported that the novel delivery device enabled placement of Alpha DaRT sources in a precise radial configuration, achieving over 95% coverage of the tumor volume.

Dr. Palmer put it plainly: "Patients with recurrent glioblastoma face one of the most difficult cancer diagnoses in medicine. There is an urgent unmet need for new therapeutic approaches that can be delivered locally while minimizing harm to surrounding healthy brain tissue."

FDA Fast-Track Status Signals Confidence

Uzi Sofer, CEO of Alpha Tau Medical, noted that the pilot study supports the company's strategy to treat cancer patients with high unmet needs. And the FDA seems to agree this is worth accelerating.

To speed up the marketing of Alpha DaRT treatment, the company was granted Food and Drug Administration Breakthrough Device Designation. They've also been accepted into the FDA's Total Product Life Cycle Advisory Program, a voluntary pilot program intended to promote innovative medical device development through early FDA engagement. Translation: the FDA is giving Alpha Tau a shorter path to market because they think this technology could actually help people who have few other options.

What the Market Is Saying

The after-hours pop reflects investor optimism about Alpha Tau's prospects. DRTS shares have gained 39.60% over the past year, and the oncology therapeutics company now carries a market capitalization of $363.47 million.

The stock closed regular trading on Tuesday at $4.23, up 8.74%, before rocketing higher after hours. Shares have traded in an annual range of $2.30 to $4.69, meaning the after-hours price of $5.30 represents a new high for the year.

With momentum in the 79th percentile, DRTS is experiencing short-term consolidation along with medium and long-term upward movement. For a small-cap biotech tackling one of medicine's toughest challenges, that kind of momentum tells you the market is paying attention.